H02.SI stock trades at S$17.04 pre-market ahead of 19 Feb earnings: what to watch next

H02.SI stock trades at S$17.04 in the SES pre-market on 17 Feb 2026 as investors position ahead of Haw Par Corporation Limited’s earnings release on 19 Feb 2026. The company reports from Singapore (SES) and combines healthcare brands, investments and property assets. Key figures to watch are EPS S$1.13, PE 14.94, and a trailing dividend of S$1.40 per share. We examine near-term earnings drivers, valuation versus the Healthcare sector, and what results could mean for the S$17.04 share price.

Earnings preview for H02.SI stock

Haw Par’s upcoming report on 19 Feb 2026 is the immediate catalyst for H02.SI stock. Analysts will focus on Healthcare segment margins driven by Tiger Balm volumes and the Investments segment fair-value swings. The company last posted EPS S$1.13 and a PE 14.94, below the sector average PE 22.17, which frames expectations for relatively muted multiple expansion.

Key financials and valuation for H02.SI stock

Balance-sheet strength is a defining feature: cash per share S$17.85 and book value per share S$18.44 against the current price of S$17.04. The price-to-book is 0.92, signalling a sub-book valuation. Free cash flow per share is S$0.28 and dividend per share is S$1.40, giving a trailing yield near 8.29%. These metrics support an income-minded case but note payout ratio above 100% at 1.24, which raises sustainability questions.

Technical setup and trading context for H02.SI stock

Pre-market action shows a tight intraday range with day low S$16.72 and day high S$17.06 on 17 Feb 2026, and volume at 224,500 shares, slightly above the 50-day average. Momentum indicators are constructive: RSI 65.56 and MACD positive, suggesting buyers are active into earnings. Support sits near the 50-day average S$16.17 and year low is S$11.30.

Meyka AI grade and analyst context

Meyka AI rates H02.SI with a score of 73.06 out of 100 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Independent sell-side targets are limited, so our grade reflects balance-sheet strength, dividend yield, and conservative valuation. These grades are not guaranteed and we are not financial advisors.

Forecasts and price targets for H02.SI stock

Meyka AI’s forecast model projects monthly S$18.16 and 12-month S$19.78 for H02.SI stock. Versus the current S$17.04, the 12-month forecast implies 16.05% upside. Shorter-term monthly projection implies 6.57% upside to S$18.16. Forecasts are model-based projections and not guarantees.

Risks and what to watch in the earnings report

Key downside risks include weaker Healthcare volumes, sharp fair-value losses on quoted investments, and pressure on dividend coverage given a payout ratio of 1.24. Watch management commentary on capital allocation, property leasing occupancy across Singapore and Malaysia, and any guidance change on Tiger Balm demand. A conservative outcome could see the stock re-price toward book value, while a beat could tighten the PB gap.

Final Thoughts

H02.SI stock at S$17.04 on 17 Feb 2026 enters earnings with a defensive balance sheet and a high trailing dividend that attracts income investors. Key positives are cash per share S$17.85, book value per share S$18.44, and a PE 14.94 below the Healthcare peer average PE 22.17. Our Meyka AI forecast model projects S$19.78 in 12 months, implying 16.05% upside from today’s price, while the monthly projection of S$18.16 implies 6.57% near-term potential. Investors should weigh the attractive yield of 8.29% against payout sustainability and the potential for investment revaluation in the results. Ahead of the 19 Feb 2026 release, focus on segment margins, investment portfolio marks, and dividend guidance; those items will drive near-term volatility. Meyka AI provides this as model-based market analysis, not investment advice

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.